Hypercoagulability: Too Many Tests, Too Much Conflicting Data
Open Access
- 1 January 2002
- journal article
- case report
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2002 (1), 353-368
- https://doi.org/10.1182/asheducation-2002.1.353
Abstract
It is now possible to identify hereditary and acquired risk factors in a substantial percentage of patients presenting with a venous thrombotic event. The clinician is faced with an ever-growing number of laboratory tests that can be ordered in such patients, and there is considerable uncertainty as to how this information should be utilized in patient management. Some have argued that widespread testing of thrombosis patients for prothrombotic abnormalities such as the factor V Leiden and prothrombin G20210A mutations has been prematurely adopted into clinical practice as there are few data that their identification leads to improved clinical outcomes. Dr. Rosendaal provides an overview of the epidemiology of venous thrombosis with an emphasis on hereditary and acquired risk factors. The presentation will include information obtained from properly designed case-control studies as well as family studies. While some have suggested treatment strategies for managing patients with hereditary thrombophilia with prior thrombotic events or for managing patients undergoing procedures associated with increased thrombotic risk, clinical decision making is complicated by the need to assess the risk of recurrence and the likely benefit of prolonged anticoagulation versus the associated bleeding risk. Drs. Bauer, Heit, and Rosendaal discuss their approaches to patient management. Case presentations are used to illustrate the impact of laboratory test results on decisions.Keywords
This publication has 83 references indexed in Scilit:
- High Plasma Levels of Factor VIII and the Risk of Recurrent Venous ThromboembolismNew England Journal of Medicine, 2000
- The Risk of Recurrent Deep Venous Thrombosis among Heterozygous Carriers of Both Factor V Leiden and the G20210A Prothrombin MutationNew England Journal of Medicine, 1999
- Tamoxifen and risk of idiopathic venous thromboembolismBritish Journal of Clinical Pharmacology, 1998
- Risk of venous thromboembolism in users of hormone replacement therapyThe Lancet, 1996
- Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen componentsThe Lancet, 1995
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- Homozygous protein S deficiency in an infant with purpura fulminansThe Journal of Pediatrics, 1990
- Incidence and Diagnosis of Deep Vein Thrombosis Associated with PregnancyActa Obstetricia et Gynecologica Scandinavica, 1983
- PULMONARY EMBOLISMThe Lancet, 1961